Spyre Therapeutics, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Spyre announced positive 12-week data from SKYLINE Part A for SPY003 (anti-IL-23), demonstrating a statistically significant 10.0-point reduction in RHI score (p<0.0001), 20% clinical remission, and 30% endoscopic improvement in 44 UC patients, with a well-tolerated safety profile consistent with the IL-23 class. Combined with previously reported positive results for SPY001 and SPY002, all three monotherapy components have now achieved proof-of-concept. Part B, evaluating pairwise combinations of these three agents, is actively enrolling with topline induction data expected in 2027.
Why this rating
Three-month clinical POC across entire IBD pipeline validates core strategy ahead of critical combination trial; material near-term value inflection point, but late-stage execution and regulatory risks remain substantial.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $89.17 ▲ 0.21% | at our read · unknown $88.98 | +10 min · unknown $88.98 ▲ 0.00% | +30 min · unknown $88.98 ▲ 0.00% | +1 hr pending | +4 hrs pending |
The stock had already moved -0.21% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.